Key Highlights
- Serena Hung, M.D., appointed as Chief Medical Officer
- Jeffrey Young appointed as Chief Financial Officer
- Atalanta Therapeutics advances its robust portfolio of 14 programs
- Company aims for IND submissions in 2025
Source: Business Wire
Notable Quotes
- “We are thrilled to welcome Jeffrey and Serena to Atalanta’s executive team as we prepare for our next phase of growth in building the leading CNS RNAi company,” – Alicia Secor, President and CEO at Atalanta Therapeutics
- “I believe Atalanta’s novel RNAi platform could provide a much-needed breakthrough to deliver better outcomes for these patients,” – Dr. Serena Hung, Chief Medical Officer at Atalanta Therapeutics
- “Atalanta’s di-siRNA technology has potential to unlock a large universe of CNS targets,” – Jeffrey Young, Chief Financial Officer at Atalanta Therapeutics
SoHC's Take
Atalanta Therapeutics’ strategic expansion of its executive team underscores the company’s commitment to advancing its innovative RNAi platform for neurological diseases. The appointments of Dr. Serena Hung and Jeffrey Young bring a wealth of expertise in clinical development and financial management, positioning Atalanta for significant progress in its pipeline. With a robust portfolio and planned IND submissions on the horizon, Atalanta is well-equipped to make substantial strides in addressing unmet needs in CNS therapeutics. This move signals a strong trajectory for the company as it continues to push the boundaries of RNAi technology in the treatment of neurodegenerative disorders.
